{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T09:19:39Z","timestamp":1774084779934,"version":"3.50.1"},"publisher-location":"Cham","reference-count":38,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319492827","type":"print"},{"value":"9783319492841","type":"electronic"}],"license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015]]},"DOI":"10.1007\/82_2015_451","type":"book-chapter","created":{"date-parts":[[2015,7,10]],"date-time":"2015-07-10T13:50:11Z","timestamp":1436536211000},"page":"447-474","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Antibiotics Clinical Development and Pipeline"],"prefix":"10.1007","author":[{"given":"Thomas","family":"Hesterkamp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,11]]},"reference":[{"key":"451_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1086\/510079","volume":"44","author":"PG Ambrose","year":"2007","unstructured":"Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL (2007) Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it\u2019s not just for mice anymore. Clin Infect Dis 44:79\u201386","journal-title":"Clin Infect Dis"},{"key":"451_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S1473-3099(12)70046-4","volume":"412","author":"PG Ambrose","year":"2012","unstructured":"Ambrose PG, Bhavnani SM, Dudley MN, Ellis-Grosse E, Rubino CM, Drusano GL (2012) New EMA guideline for antimicrobial development. Lancet Infect Dis 412:265\u2013266","journal-title":"Lancet Infect Dis"},{"key":"451_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0924-8579(02)00022-5","volume":"19","author":"D Andes","year":"2002","unstructured":"Andes D, Craig WA (2002) Animal models of pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 19:261\u2013268","journal-title":"Int J Antimicrob Agents"},{"key":"451_CR4","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1001\/jama.2014.17103","volume":"313","author":"N Bagdasarian","year":"2015","unstructured":"Bagdasarian N, Rao K, Malani PN (2015) Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA 313:398\u2013408","journal-title":"JAMA"},{"key":"451_CR5","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1182\/asheducation-2013.1.428","volume":"2013","author":"M Bassetti","year":"2013","unstructured":"Bassetti M, Righi E (2013) Multidrug-resistant bacteria: what is the threat? Hematol Am Soc Hematol Educ Prog 2013:428\u2013432","journal-title":"Hematol Am Soc Hematol Educ Prog"},{"key":"451_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1476-0711-12-22","volume":"12","author":"M Bassetti","year":"2013","unstructured":"Bassetti M, Merelli M, Temperoni C, Astilean A (2013) New antibiotics for bad bugs: where are we? Ann Clin Microbiol Antimicrob 12:22","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"451_CR7","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1093\/jac\/dku572","volume":"70","author":"R Bax","year":"2015","unstructured":"Bax R, Green S (2015) Antibiotics: the changing regulatory and pharmaceutical industry paradigm. J Antimicrob Chemother 70:1281\u20131284","journal-title":"J Antimicrob Chemother"},{"key":"451_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/595011","volume":"48","author":"HW Boucher","year":"2009","unstructured":"Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J (2009) Bad bugs, no drugs: no ESKAPE! an update from the Infectious Diseases Society of America. Clin Infect Dis 48:1\u201312","journal-title":"Clin Infect Dis"},{"key":"451_CR9","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1093\/cid\/cit152","volume":"56","author":"HW Boucher","year":"2013","unstructured":"Boucher HW, Talbot GH, Benjamin DK Jr, Bradley J, Guidos RJ, Jones RN, Murray BE, Bonomo RA, Gilbert D (2013) Infectious Diseases Society of America. 10\u00a0\u00d7\u00a0\u203220 progress development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 56:1685\u20131694","journal-title":"Clin Infect Dis"},{"key":"451_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/nyas.12023","volume":"1277","author":"K Bush","year":"2013","unstructured":"Bush K (2013) Proliferation and significance of clinically relevant \u03b2-lactamases. Ann N Y Acad Sci 1277:84\u201390","journal-title":"Ann N Y Acad Sci"},{"key":"451_CR11","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1146\/annurev-med-081210-144458","volume":"3","author":"DP Calfee","year":"2012","unstructured":"Calfee DP (2012) Crisis in hospital-acquired, healthcare-associated infections. Annu Rev Med 3:359\u2013371","journal-title":"Annu Rev Med"},{"key":"451_CR12","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1128\/AAC.01989-12","volume":"57","author":"JL Crandon","year":"2013","unstructured":"Crandon JL, Nicolau DP (2013) Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-\u03b2-lactamase producers. Antimicrob Agents Chemother 57:3299\u20133306","journal-title":"Antimicrob Agents Chemother"},{"key":"451_CR13","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1128\/AAC.00826-13","volume":"58","author":"SM Drawz","year":"2014","unstructured":"Drawz SM, Papp-Wallace KM, Bonomo RA (2014) New \u03b2-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother 58:1835\u20131846","journal-title":"Antimicrob Agents Chemother"},{"key":"451_CR14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/QCO.0000000000000141","volume":"28","author":"J Garnacho-Montero","year":"2015","unstructured":"Garnacho-Montero J, Escoresca-Ortega A, Fern\u00e1ndez-Delgado E (2015) Antibiotic de-escalation in the ICU: how is it best done? Curr Opin Infect Dis 28:193\u2013198","journal-title":"Curr Opin Infect Dis"},{"key":"451_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jhin.2015.01.008","volume":"89","author":"PM Hawkey","year":"2015","unstructured":"Hawkey PM (2015) Multidrug-resistant gram-negative bacteria: a product of globalization. J Hosp Infect 89:241\u2013247","journal-title":"J Hosp Infect"},{"key":"451_CR16","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1093\/jac\/dks009","volume":"67","author":"PG Higgins","year":"2012","unstructured":"Higgins PG, Stefanik D, Page MG, Hackel M, Seifert H (2012) In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-non-susceptible Acinetobacter baumannii. J Antimicrob Chemother 67:1167\u20131169","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 3","key":"451_CR17","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1086\/677819","volume":"35","author":"SS Huang","year":"2014","unstructured":"Huang SS, Septimus E, Avery TR, Lee GM, Hickok J, Weinstein RA, Moody J, Hayden MK, Perlin JB, Platt R, Ray GT (2014) Cost savings of universal decolonization to prevent intensive care unit infection: implications of the REDUCE MRSA trial. Infect Control Hosp Epidemiol 35(Suppl 3):S23\u2013S31","journal-title":"Infect Control Hosp Epidemiol"},{"key":"451_CR18","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1093\/cid\/cis688","volume":"55","author":"Infectious Diseases Society of America","year":"2012","unstructured":"Infectious Diseases Society of America (2012) White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. Clin Infect Dis 55:1031\u20131046","journal-title":"Clin Infect Dis"},{"key":"451_CR19","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1517\/14656566.2014.914172","volume":"15","author":"I Karaiskos","year":"2014","unstructured":"Karaiskos I, Giamarellou H (2014) Multidrug-resistant and extensively drug-resistant gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother 15:1351\u20131370","journal-title":"Expert Opin Pharmacother"},{"key":"451_CR20","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/nm0714-690","volume":"20","author":"AB Keener","year":"2014","unstructured":"Keener AB (2014) First QIDP drug approved, but designation may fail urgent needs. Nat Med 20:690\u2013691","journal-title":"Nat Med"},{"key":"451_CR21","doi-asserted-by":"publisher","first-page":"e86634","DOI":"10.1371\/journal.pone.0086634","volume":"9","author":"M Koningstein","year":"2014","unstructured":"Koningstein M, van der Bij AK, de Kraker ME, Monen JC, Muilwijk J, de Greeff SC, Geerlings SE, van Hall MA (2014) ISIS-AR Study Group. Recommendations for the empirical treatment of complicated urinary tract infections using surveillance data on antimicrobial resistance in the Netherlands. PLoS ONE 9:e86634","journal-title":"PLoS ONE"},{"key":"451_CR22","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/ddr.21176","volume":"75","author":"A Kumar Kakkar","year":"2014","unstructured":"Kumar Kakkar A, Dahiya N (2014) The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space. Drug Dev Res 75:231\u2013234","journal-title":"Drug Dev Res"},{"key":"451_CR23","doi-asserted-by":"publisher","first-page":"6913","DOI":"10.1128\/AAC.03267-14","volume":"58","author":"SH MacVane","year":"2014","unstructured":"MacVane SH, Crandon JL, Nichols WW, Nicolau DP (2014) In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates. Antimicrob Agents Chemother 58:6913\u20136919","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 3","key":"451_CR24","doi-asserted-by":"publisher","first-page":"S104","DOI":"10.1093\/cid\/ciu530","volume":"59","author":"MR McKellar","year":"2014","unstructured":"McKellar MR, Fendrick AM (2014) Innovation of novel antibiotics: an economic perspective. Clin Infect Dis 59(Suppl 3):S104\u2013S107","journal-title":"Clin Infect Dis"},{"key":"451_CR25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/clpt.2014.116","volume":"96","author":"S Nambiar","year":"2014","unstructured":"Nambiar S, Laessig K, Toerner J, Farley J, Cox E (2014) Antibacterial drug development: challenges, recent developments, and future considerations. Clin Pharmacol Ther 96:147\u2013149","journal-title":"Clin Pharmacol Ther"},{"key":"451_CR26","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/j.1469-0691.2012.03822.x","volume":"18","author":"GR Nimmo","year":"2012","unstructured":"Nimmo GR (2012) USA300 abroad: global spread of a virulent strain of community-associated methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 18:725\u2013734","journal-title":"Clin Microbiol Infect"},{"key":"451_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.coph.2014.09.008","volume":"18","author":"MG Page","year":"2014","unstructured":"Page MG, Bush K (2014) Discovery and development of new antibacterial agents targeting Gram-negative bacteria in the era of pandrug resistance: is the future promising? Curr Opin Pharmacol 18:91\u201397","journal-title":"Curr Opin Pharmacol"},{"key":"451_CR28","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1128\/CMR.00033-13","volume":"26","author":"MJ Pucci","year":"2013","unstructured":"Pucci MJ, Bush K (2013) Investigational antimicrobial agents of 2013. Clin Microbiol Rev 26:792\u2013821","journal-title":"Clin Microbiol Rev"},{"key":"451_CR29","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S1473-3099(12)70293-1","volume":"13","author":"JH Rex","year":"2013","unstructured":"Rex JH, Eisenstein BI, Alder J, Goldberger M, Meyer R, Dane A, Friedland I, Knirsch C, Sanhai WR, Tomayko J, Lancaster C, Jackson J (2013) A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect Dis 13:269\u2013275","journal-title":"Lancet Infect Dis"},{"key":"451_CR30","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1086\/533452","volume":"197","author":"LB Rice","year":"2008","unstructured":"Rice LB (2008) Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 197:1079\u20131081","journal-title":"J Infect Dis"},{"key":"451_CR31","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/archinternmed.2011.26","volume":"171","author":"B Spellberg","year":"2011","unstructured":"Spellberg B (2011) The antibiotic crisis: can we reverse 65\u00a0years of failed stewardship? Arch Intern Med 171:1080\u20131081","journal-title":"Arch Intern Med"},{"key":"451_CR32","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/cc13948","volume":"18","author":"B Spellberg","year":"2012","unstructured":"Spellberg B (2014) The future of antibiotics. Crit Care 18:228","journal-title":"Crit Care"},{"key":"451_CR33","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/clpt.2014.106","volume":"96","author":"B Spellberg","year":"2014","unstructured":"Spellberg B, Shlaes D (2014) Prioritized current unmet needs for antibacterial therapies. Clin Pharmacol Ther 96:151\u2013153","journal-title":"Clin Pharmacol Ther"},{"key":"451_CR34","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nrd3560-c1","volume":"11","author":"B Spellberg","year":"2012","unstructured":"Spellberg B, Sharma P, Rex JH (2012) The critical impact of time discounting on economic incentives to overcome the antibiotic market failure. Nat Rev Drug Discov 11:168","journal-title":"Nat Rev Drug Discov"},{"key":"451_CR35","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1126\/science.1182749","volume":"327","author":"N Srinivas","year":"2010","unstructured":"Srinivas N, Jetter P, Ueberbacher BJ, Werneburg M, Zerbe K, Steinmann J, Van der Meijden B, Bernardini F, Lederer A, Dias RL, Misson PE, Henze H, Zumbrunn J, Gombert FO, Obrecht D, Hunziker P, Schauer S, Ziegler U, K\u00e4ch A, Eberl L, Riedel K, DeMarco SJ, Robinson JA (2010) Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science 327:1010\u20131013","journal-title":"Science"},{"key":"451_CR36","doi-asserted-by":"crossref","unstructured":"Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G, Falcone M, Frank U, Kahlmeter G, Pan A, Petrosillo N, Rodr\u00edguez-Ba\u00f1o J, Singh N, Venditti M, Yokoe DS, Cookson B (2014) European Society of Clinical Microbiology. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect 20, Suppl 1:1\u201355","DOI":"10.1111\/1469-0691.12427"},{"key":"451_CR37","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/clpt.2014.107","volume":"96","author":"JF Tomayko","year":"2014","unstructured":"Tomayko JF, Rex JH, Tenero DM, Goldberger M, Eisenstein BI (2014) The challenge of antimicrobial resistance: new regulatory tools to support product development. Clin Pharmacol Ther 96:166\u2013168","journal-title":"Clin Pharmacol Ther"},{"key":"451_CR38","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1128\/CMR.00010-14","volume":"27","author":"M Unemo","year":"2014","unstructured":"Unemo M, Shafer WM (2014) Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev 27:587\u2013613","journal-title":"Clin Microbiol Rev"}],"container-title":["Current Topics in Microbiology and Immunology","How to Overcome the Antibiotic Crisis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/82_2015_451","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T03:16:10Z","timestamp":1675134970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/82_2015_451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"ISBN":["9783319492827","9783319492841"],"references-count":38,"URL":"https:\/\/doi.org\/10.1007\/82_2015_451","relation":{},"ISSN":["0070-217X","2196-9965"],"issn-type":[{"value":"0070-217X","type":"print"},{"value":"2196-9965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]},"assertion":[{"value":"11 July 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}